Key result
ECMO is linked to a ~30% larger furosemide distribution volume in neonates and infants.
Why the study?
Optimal dosing of furosemide for fluid overload in critically ill children supported with ECMO was unknown because ECMO may alter furosemide exposure.
Does a calibrated initial bolus dose of furosemide improve the time to achieve steady-state plasma concentrations in critically ill children supported by ECMO compared to continuous infusions without an initial bolus?
Observational (n=10)
Does a calibrated initial bolus dose of furosemide improve the time to achieve steady-state plasma concentrations in critically ill children supported by ECMO compared to continuous infusions without an initial bolus?
Because ECMO increases the apparent volume of distribution of furosemide by over 30% in neonates and infants without direct circuit extraction, utilizing calibrated initial bolus doses achieves steady-state plasma concentrations more than 3 hours faster than continuous infusions alone.
Answers are grounded in this paper and cite their sources.
Supports PBPK-guided furosemide dosing in pediatric ECMO; extends models to this setting but leaves open larger prospective validation.
Extracorporeal membrane oxygenation (ECMO) is an established technology that provides life-saving mechanical support for critically ill children. In these children, fluid overload is commonly treated with furosemide; however, optimal dosing of furosemide is unknown in children supported with ECMO because ECMO may alter furosemide exposure. In this work, human blood-primed ex vivo experiments quantified red blood cell partitioning and extraction of furosemide by the ECMO circuit. Furosemide partitioned into red blood cells but was not extracted by ECMO circuits. These data then parameterized a pediatric physiologically based pharmacokinetic (PBPK) model of furosemide in children with and without ECMO. Next, plasma furosemide concentrations from 10 critically ill children supported by ECMO were used to evaluate PBPK model performance, with the optimized model achieving average fold error and absolute average fold error of 1.02 and 1.67, respectively. The optimized PBPK model also predicted that ECMO increases apparent volume of distribution by a median of > 30% in neonates and infants. Finally, population PBPK simulations with the optimized PBPK model provided initial bolus doses that most rapidly achieve steady-state plasma furosemide concentrations with and without ECMO. These calibrated initial bolus doses achieved steady-state plasma furosemide concentrations > 3 h faster than continuous infusions without an initial bolus dose, and this improvement was most pronounced in neonates and infants on ECMO. Overall, this work supports comparatively larger initial bolus doses for neonates and infants on ECMO, and provides calibrated initial bolus doses based on plasma exposure for critically ill children.
No takes yet. Share an insight, caveat, or question.
Hunt et al. (2026) conducted an observational in Fluid overload in critically ill children supported by ECMO (n=10). Furosemide on ECMO vs. Furosemide without ECMO or continuous infusion without an initial bolus dose was evaluated on Furosemide pharmacokinetics (apparent volume of distribution and time to steady-state plasma concentration). ECMO predicted a >30% median increase in furosemide apparent volume of distribution in neonates/infants, and calibrated initial bolus doses achieved steady-state >3 h faster than infusion alone.
Synapse has enriched 10 related papers. Consider them for comparative context: